Biocardia, Inc. (BCDA) Stock Price & Analysis
Biocardia, Inc. (BCDA) fell 6.55% to USD 0.86 as of June 10, 2026 at 03:07 UTC, according to Nexqual real-time market data.
BCDA last closed at USD 0.92; the session ranged USD 0.83–0.92 on volume of 2,203,262 shares. Market capitalization is $12.80M, with a 52-week range of USD 0.84–2.45 (NCM). Source: Nexqual, June 10, 2026 at 03:07 UTC.
Key Statistics (as of June 10, 2026 at 03:07 UTC)
| Price | USD 0.86 |
|---|---|
| Change | ▼ 6.55% (down) |
| Previous Close | USD 0.92 |
| Open | USD 0.84 |
| Day Range | USD 0.83 – 0.92 |
| 52-Week Range | USD 0.84 – 2.45 |
| Volume | 2,203,262 shares |
| Market Cap | $12.80M |
| Exchange | NCM |
Technical Analysis (BCDA)
Nexqual's technical model rates BCDA "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:07 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.66 (neutral) |
| vs SMA50 | Below (USD 1.08) |
| MACD | -0.05 (negative) |
Analyst Ratings (BCDA)
Wall Street analysts rate BCDA "None" based on 2 analysts, with a mean price target of USD 15.5 (range USD 6–25), per Nexqual as of June 10, 2026 at 03:07 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 15.5 |
| High Target | USD 25 |
| Low Target | USD 6 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (BCDA)
| EPS Estimate | USD -0.19 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.21 vs est -0.17 ▼ miss |
| 2025-12-31 | USD -0.06 vs est -0.2 ▲ beat |
| 2025-09-30 | USD -0.24 vs est -0.25 ▲ beat |
| 2025-06-30 | USD -0.4 vs est -0.5 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financials & Fundamentals (BCDA)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| Current Ratio | 0.41 |
| Total Cash | $951,000 |
| Total Debt | $412,000 |
| Free Cash Flow | $-4.94M |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Financial Health Score (BCDA)
Nexqual rates Biocardia, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:07 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $951K cash, no debt |
| Cash Flow | Weak — Operating cash flow -$7M |
| Efficiency | Mixed — No data |
Ownership (BCDA)
| Insider Ownership | +22.96% |
|---|---|
| Institutional Ownership | +5.45% |
| Shares Outstanding | 14.88M |
| Float | 8.76M |
| Short % of Float | +3.46% |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
Leadership (BCDA)
Biocardia, Inc. is led by Peter A. Altman (age 58), CEO, President & Director, per Nexqual as of June 10, 2026 at 03:07 UTC.
| CEO, President & Director | Peter A. Altman (age 58) |
|---|---|
| Chief Financial Officer | David McClung (age 62) |
| Senior Vice President of Devices | Edward M. Gillis (age 63) |
Major Backers & Investors (BCDA)
Notable institutional backers of Biocardia, Inc. include CM Management, LLC, Fidelity, Citadel, according to Nexqual as of June 10, 2026 at 03:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| CM Management, LLC | 1.14% |
| Fidelity | 0.66% |
| Citadel | 0.56% |
| Susquehanna International Group, LLP | 0.34% |
| Pingora Partners LLC | 0.31% |
| Brown Advisory Inc. | 0.31% |
| Xtx Topco Ltd | 0.21% |
| Virtu Financial LLC | 0.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.78% |
| Geode Capital | 0.83% |
Source: Nexqual, June 10, 2026 at 03:07 UTC.
From Biocardia, Inc.'s Latest SEC 10-K Filing (filed 2026-03-24)
Key Strengths & Strategy (as disclosed to the SEC)
- BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.
- The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
- It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome.
- In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers.
Partnerships
- It has a license and distribution agreement with Biomet Biologics, LLC.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ADIL | Adial Pharmaceuticals, Inc | USD 2.13 | ▼ 3.62% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| LIXT | Lixte Biotechnology Holdings, I | USD 6.87 | ▼ 1.86% |
| ARDS | Aridis Pharmaceuticals Inc. | USD 0 | ▲ 0% |
| PHIO | Phio Pharmaceuticals Corp. | USD 1.08 | ▲ 1.89% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:07 UTC. This page is informational and not investment advice.